Additionally, inhibition of the ERK/Mnk1/eIF4E by this agent enhances dasatinib sensitivity in chronic myeloid leukemia (CML) (Liu et al. 2016). Here, EIF4E is linked to chronic myelogenous leukemia, BCR-ABL1 positive.